Most Read News

Corporate results have affected the course of market movement in the past 1 week.

The lender will start discussions are likely to start around May and by the end of the first quarter.

Bullish momentum in the stock after it won two major projects recently.

Ipca’s acquisition of Unichem for Rs18 billion (59% stake) has understandably raised capital allocation concerns, given the deal would increase Ipca’s exposure to inherently low-margin, low returns US/Exports business, and company’s India formulations revenue share will also decline from ~45% to ~37% post the deal.

HCL Tech, and Tata Consultancy Services saw an almost 65% drop in hiring

ManKind Pharma is one of the largest pharma companies of India, which focuses on the development of a diverse range of pharma products.

As per the regulatory filing, the record date for the dividend declared is June 30, 2023 and will be credited in shareholders account around July 28, 2023.

The Association of Mutual Funds of India (AMFI), apart from releasing the monthly and quarterly details of mutual fund flows, also discloses some key trends.

In company’s press statement, CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology.

The company has classified the orders ranging between Rs 1,000 crore to Rs 2,500 crore in size as a significant order.